Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) CEO Mark J. Foley sold 70,447 shares of the business’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $34.55, for a total value of $2,433,943.85. Following the completion of the sale, the chief executive officer now owns 923,212 shares […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) CEO Mark J. Foley sold 70,447 shares of Revance Therapeutics stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $34.55, for a total value of $2,433,943.85. Following the completion of the transaction, the chief executive officer now owns […]
Revance Therapeutics (NASDAQ:RVNC – Get Rating) had its target price hoisted by Piper Sandler from $39.00 to $50.00 in a research note published on Wednesday, The Fly reports. A number of other analysts have also recently issued reports on the stock. HC Wainwright increased their price objective on shares of Revance Therapeutics from $42.00 to […]
Revance Therapeutics (NASDAQ:RVNC – Get Rating) had its target price hoisted by HC Wainwright from $42.00 to $48.00 in a research note issued to investors on Wednesday morning, The Fly reports. Several other equities analysts also recently commented on RVNC. StockNews.com upgraded Revance Therapeutics from a sell rating to a hold rating in a research […]
Revance Therapeutics (NASDAQ:RVNC – Get Rating) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.01, Briefing.com reports. The firm had revenue of $49.33 million for the quarter, compared to analysts’ expectations of $46.21 million. Revance Therapeutics had […]